The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...
PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...
Navratri fasting, a blend of devotion and discipline, sees millions abstaining from food for nine days. While short fasts ...
After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a ...
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...
The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, making it the first once-daily oral pill available for patients in the ...
Amgen Inc.'s healthy commercial product portfolio and pipeline position the company well for long-term value creation. Read ...
Designed to provide broad exposure to the Utilities - Infrastructure segment of the equity market, the First Trust NASDAQ ...
The upcoming Think 20 Summit Dialogue, convened by the UK’s Foreign, Commonwealth & Development Office, the Association for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback